At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01541 IMMUNEONCO-B
Not Yet Opened 12-17 16:08:10
6.080
-0.080
-1.30%
High6.210
Low5.960
Vol872.80K
Open6.160
D1 Closing6.160
Amplitude4.06%
Mkt Cap2.63B
Tradable Cap2.55B
Total Shares432.00M
T/O5.30M
T/O Rate0.21%
Tradable Shares420.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
ImmuneOnco (01541) Announces Registered Share Capital Increase as of November 2025
IMMUNEONCO-B (01541): Drug Evaluation Center Approves Phase III Clinical Study Protocol for IMM0306 in Treating Relapsed/Refractory Follicular Lymphoma
ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in the development of tumor immunotherapy. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets.